{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:44:19Z","timestamp":1791333859019,"version":"4.3.1"},"update-to":[{"DOI":"10.1371\/journal.pntd.0009903","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000}}],"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Drugs for Neglected Diseases"},{"name":"UK aid, UK","award":["Grants 2006-2008 and 2008-2013"],"award-info":[{"award-number":["Grants 2006-2008 and 2008-2013"]}]},{"DOI":"10.13039\/501100003388","name":"Minist\u00e8re des Affaires \u00c9trang\u00e8res","doi-asserted-by":"publisher","award":["FSP 2006-83"],"award-info":[{"award-number":["FSP 2006-83"]}],"id":[{"id":"10.13039\/501100003388","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011061","name":"Agence Fran\u00e7aise de D\u00e9veloppement","doi-asserted-by":"publisher","award":["CZZ 1732"],"award-info":[{"award-number":["CZZ 1732"]}],"id":[{"id":"10.13039\/501100011061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011723","name":"Canton de Gen\u00e8ve","doi-asserted-by":"publisher","award":["Convention 2010-2012"],"award-info":[{"award-number":["Convention 2010-2012"]}],"id":[{"id":"10.13039\/501100011723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004892","name":"Agencia Espa\u00f1ola de Cooperaci\u00f3n Internacional para el Desarrollo","doi-asserted-by":"publisher","award":["MoU 2007-2008"],"award-info":[{"award-number":["MoU 2007-2008"]}],"id":[{"id":"10.13039\/501100004892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009131","name":"Direktion f\u00fcr Entwicklung und Zusammenarbeit","doi-asserted-by":"publisher","award":["642.33\/2010\/0779\/02 PZO\/NID"],"award-info":[{"award-number":["642.33\/2010\/0779\/02 PZO\/NID"]}],"id":[{"id":"10.13039\/100009131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008196","name":"M\u00e9decins Sans Fronti\u00e8res","doi-asserted-by":"publisher","award":["MoU 2006-2008"],"award-info":[{"award-number":["MoU 2006-2008"]}],"id":[{"id":"10.13039\/100008196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medicor Foundation","award":["2007 grant"],"award-info":[{"award-number":["2007 grant"]}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nifurtimox-eflornithine combination therapy (NECT) for the treatment of second stage gambiense human African trypanosomiasis (HAT) was added to the World Health Organization\u2019s Essential Medicines List in 2009 after demonstration of its non-inferior efficacy compared to eflornithine therapy. A study of NECT use in the field showed acceptable safety and high efficacy until hospital discharge in a wide population, including children, pregnant and breastfeeding women, and patients with a HAT treatment history. We present here the effectiveness results after the 24-month follow-up visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methodology\/Principal findings<\/jats:title>\n                    <jats:p>In a multicenter, open label, single arm phase IIIb study, second stage gambiense HAT patients were treated with NECT in the Democratic Republic of Congo. Clinical cure was defined 24 months after treatment as survival without clinical and\/or parasitological signs of HAT. Of the 629 included patients, 619 (98.4%) were discharged alive after treatment and were examined for the presence of trypanosomes, white blood cell count in cerebro-spinal fluid, and disease symptoms. The clinical cure rate of 94.1% was comparable for all subpopulations analyzed at the 24-month follow-up visit. Self-reported adverse events during follow-up were few and concerned mainly nervous system disorders, infections, and gastro-intestinal disorders. Overall, 28 patients (4.3%) died during the course of the trial. The death of 16 of the 18 patients who died during the follow-up period was assessed as unlikely or not related to NECT. Within 24 months, eight patients (1.3%) relapsed and received rescue treatment. Sixteen patients were completely lost to follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions\/Significance<\/jats:title>\n                    <jats:p>NECT treatment administered under field conditions was effective and sufficiently well tolerated, no major concern arose for children or pregnant or breastfeeding women. Patients with a previous HAT treatment history had the same response as those who were na\u00efve. In conclusion, NECT was confirmed as effective and appropriate for use in a broad population, including vulnerable subpopulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      The trial is registered at ClinicalTrials.gov, number\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00906880\" xlink:type=\"simple\">NCT00906880<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0009903","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T13:42:10Z","timestamp":1636378930000},"page":"e0009903","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5621-2676","authenticated-orcid":true,"given":"Andrea","family":"Kuemmerle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1593-9697","authenticated-orcid":true,"given":"Caecilia","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Kande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Mutombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medard","family":"Ilunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Lumpungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Mutanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pathou","family":"Nganzobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8253-1128","authenticated-orcid":true,"given":"Digas Ngolo","family":"Tete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mays","family":"Kisala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5418-1984","authenticated-orcid":true,"given":"Christian","family":"Burri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-8015","authenticated-orcid":true,"given":"Severine","family":"Blesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-1014","authenticated-orcid":true,"given":"Olaf","family":"Valverde Mordt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"pntd.0009903.ref001","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/S0140-6736(17)31510-6","article-title":"Human African trypanosomiasis","volume":"390","author":"P B\u00fcscher","year":"2017","journal-title":"The Lancet"},{"key":"pntd.0009903.ref002","first-page":"257","article-title":"Epidemiology of human African trypanosomiasis","volume":"6","author":"JR Franco","year":"2014","journal-title":"Clin Epidemiol"},{"key":"pntd.0009903.ref003","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12942-015-0013-9","article-title":"Human African trypanosomiasis in the Democratic Republic of the Congo: disease distribution and risk","volume":"14","author":"C Lumbala","year":"2015","journal-title":"Int J Health Geogr"},{"key":"pntd.0009903.ref004","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1017\/S0031182013002102","article-title":"The journey towards elimination of gambiense human African trypanosomiasis: not far, nor easy","volume":"141","author":"JR Franco","year":"2014","journal-title":"Parasitology"},{"issue":"5","key":"pntd.0009903.ref005","doi-asserted-by":"crossref","first-page":"e0008261","DOI":"10.1371\/journal.pntd.0008261","article-title":"Monitoring the elimination of human African trypanosomiasis at continental and country level: Update to 2018","volume":"14","author":"JR Franco","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009903.ref006","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.trstmh.2008.09.005","article-title":"Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Medecins Sans Frontieres programmes","volume":"103","author":"M Balasegaram","year":"2009","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0009903.ref007","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"G Priotto","year":"2009","journal-title":"Lancet"},{"key":"pntd.0009903.ref008","unstructured":"WHO Model Lists of Essential Medicines, 16th list. 2010. Available: http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/"},{"key":"pntd.0009903.ref009","unstructured":"WHO Model Lists of Essential Medicines for children, 4th list. 2013. Available: http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/"},{"key":"pntd.0009903.ref010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-019-1051-6","article-title":"Fexinidazole: First Global Approval","volume":"79","author":"ED Deeks","year":"2019","journal-title":"Drugs"},{"key":"pntd.0009903.ref011","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0140-6736(17)32758-7","article-title":"Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial","volume":"391","author":"VKBK Mesu","year":"2018","journal-title":"The Lancet"},{"key":"pntd.0009903.ref012","doi-asserted-by":"crossref","first-page":"e0007381","DOI":"10.1371\/journal.pntd.0007381","article-title":"The European Medicines Agency\u2019s scientific opinion on oral fexinidazole for human African trypanosomiasis","volume":"13","author":"E Pelfrene","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009903.ref013","unstructured":"WHO interim guidelines for the treatment of gambiense human African trypanosomiasis. 2019. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK545514\/"},{"key":"pntd.0009903.ref014","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S1473-3099(19)30612-7","article-title":"New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice","volume":"20","author":"AK Lindner","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"pntd.0009903.ref015","doi-asserted-by":"crossref","first-page":"e1920","DOI":"10.1371\/journal.pntd.0001920","article-title":"hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness","volume":"6","author":"C Schmid","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009903.ref016","doi-asserted-by":"crossref","first-page":"e0008028","DOI":"10.1371\/journal.pntd.0008028","article-title":"Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo","volume":"14","author":"A Kuemmerle","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009903.ref017","unstructured":"Recommendations of the informal consultation on issues for clinical product development for human African trypanosomiasis (2007). Available: http:\/\/www.who.int\/trypanosomiasis_african\/resources\/who_cds_ntd_idm_2007.1\/en\/"},{"key":"pntd.0009903.ref018","doi-asserted-by":"crossref","DOI":"10.1186\/s13071-018-2634-x","article-title":"A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda","volume":"11","author":"F Kansiime","year":"2018","journal-title":"Parasit Vectors"},{"key":"pntd.0009903.ref019","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1371\/journal.pctr.0010039","article-title":"Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda","volume":"1","author":"G Priotto","year":"2006","journal-title":"PLoS Clin Trials"},{"key":"pntd.0009903.ref020","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1371\/journal.pntd.0000064","article-title":"Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series","volume":"1","author":"F Checchi","year":"2007","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009903.ref021","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/cid\/cis886","article-title":"Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: M\u00e9decins Sans Fronti\u00e8res experience in the Democratic Republic of the Congo","volume":"56","author":"E Alirol","year":"2013","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"pntd.0009903.ref022","first-page":"93","article-title":"Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis","volume":"3","author":"JR Franco","year":"2012","journal-title":"Res Rep Trop Med"},{"key":"pntd.0009903.ref023","first-page":"39","article-title":"Advances in sleeping sickness therapy","volume":"72","author":"S VanNieuwenhove","year":"1992","journal-title":"Ann Soc Belg Med Trop"},{"key":"pntd.0009903.ref024","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0035-9203(93)90044-Q","article-title":"Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness","volume":"87","author":"F Milord","year":"1993","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"7646","key":"pntd.0009903.ref025","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1136\/bmj.39485.592674.BE","article-title":"Safety and efficacy of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study","volume":"336","author":"G Priotto","year":"2008","journal-title":"BMJ"},{"key":"pntd.0009903.ref026","unstructured":"Implementing the WHO Roadmap on neglected tropical diseases\u2013partners celebrate five years of collaboration (2017). Available: http:\/\/www.who.int\/neglected_diseases\/news\/WHO_Roadmap_five_years_of_collaboration\/en\/"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0009903","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009903","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T14:14:12Z","timestamp":1637244852000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009903"}},"subtitle":[],"editor":[{"given":"Philippe","family":"B\u00fcscher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0009903","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]}}}